United States Melanoma Diagnostics And Therapeutics Market

United States Melanoma Diagnostics And Therapeutics Market Analysis

The United States Melanoma Diagnostics And Therapeutics Market size is estimated at USD 3.27 billion in 2025, and is expected to reach USD 5.34 billion by 2030, at a CAGR of 10.26% during the forecast period (2025-2030).

The United States melanoma diagnostics and therapeutics market is witnessing significant growth, driven by the increasing prevalence of melanoma and nonmelanoma skin cancer (NMSC), government initiatives, and advancements in diagnostic technologies. Melanoma, a severe form of skin cancer, requires early detection and effective treatment, which has led to a surge in demand for innovative diagnostic and therapeutic solutions. The market is poised for further expansion as stakeholders address the growing burden of skin cancer through enhanced awareness, product innovation, and supportive policies.

Melanoma and NMSC are among the most frequently diagnosed cancers in the United States. Contributing factors include prolonged exposure to ultraviolet (UV) radiation, increased outdoor activities, changing clothing trends, longer life expectancy, ozone depletion, genetic predispositions, and immune suppression in certain cases. For instance, according to the American Cancer Society (ACS), approximately 108,207 new skin cancer cases, including 100,649 melanoma cases, are expected to be diagnosed in 2024. This rising prevalence directly drives the demand for advanced diagnostic tools and effective therapeutic solutions, thereby fueling market growth.

Government and public organizations are playing a pivotal role in promoting skin cancer diagnostics, which is positively impacting the market. For instance, the Centers for Disease Control and Prevention (CDC) and the National Cancer Institute (NCI) collaborate to monitor skin cancer trends, assess risk-related behaviors, and track progress toward achieving Healthy People objectives. Additionally, initiatives like the American Academy of Dermatology's annual Skin Cancer Awareness Month in May aim to educate the public about skin cancer risks and prevention. Similarly, an increase in awareness campaigns is expected to raise the demand for diagnostic and therapeutic products and is anticipated to boost market growth over the forecast period. For instance, in May 2023, PathologyWatch, a full-service digital dermatopathology solution, recognized May as Melanoma and Skin Cancer Awareness Month with its public awareness campaign. Such efforts are expected to increase the adoption of melanoma diagnostic and therapeutic products, thereby contributing to market expansion.

Product innovation and launches by key market players are further enhancing the availability and accessibility of advanced diagnostic tools. For example, in July 2023, DeepX Diagnostics Inc. received United States Food and Drug Administration (FDA) clearance for its DermoSight digital dermatoscope, designed for teledermatology screening of suspicious skin lesions. Similarly, in May 2023, DermaSensor validated its handheld, non-invasive device for skin cancer detection, showcasing the potential of technological advancements to improve diagnostic accuracy and efficiency. These developments are expected to strengthen the competitive landscape and drive market growth.

In conclusion, the United States melanoma diagnostics and therapeutics market is set to grow significantly, supported by the increasing prevalence of skin cancer, proactive government initiatives, and continuous product innovation. However, challenges such as high therapy costs and stringent regulatory frameworks may hinder growth to some extent.

United States Melanoma Diagnostics And Therapeutics Market Trends

Immunotherapy is Expected to Witness Significant Growth Over the Forecast Period

Immunotherapy has significantly advanced melanoma treatment, particularly for advanced and metastatic stages. By utilizing the body's immune system to identify and eliminate melanoma cells, therapies such as immune checkpoint inhibitors and cytokine-based treatments have substantially enhanced survival outcomes. The introduction of drugs like nivolumab, pembrolizumab, and ipilimumab has set new standards in melanoma care, driving growth in the immunotherapy segment.

The United States Food and Drug Administration (FDA) has approved several immunotherapeutic agents for melanoma, including innovative combination therapies. For example, the approval of nivolumab with relatlimab has improved treatment efficacy by targeting multiple immune pathways. These advancements have expanded the therapeutic options available for melanoma care. A December 2024 study published in the Archives of Dermatological Research demonstrated the relatlimab/nivolumab combination's high efficacy and safety for advanced melanoma patients, further strengthening the immunotherapy segment's growth potential.

Additionally, the increasing launch of immunotherapy drugs in the United States is expected to propel the segment's expansion. For instance, in February 2024, the FDA approved Amtagvi (lifileucel), a novel T cell immunotherapy developed by Iovance Biotherapeutics Inc. This therapy is specifically designed for adult patients with advanced melanoma that is either unresectable or has metastasized. Eligibility for this treatment requires prior therapies, including a programmed death-1 (PD-1) blocking antibody and, for patients with the BRAF V600 mutation, a BRAF inhibitor, either alone or in combination with a mitogen-activated protein kinase (MEK) inhibitor. This approval marks a significant milestone in melanoma treatment, further boosting the immunotherapy segment.

In conclusion, the demonstrated effectiveness of immunotherapy in combating skin cancer, coupled with the continuous introduction of innovative products, is expected to drive substantial growth in the immunotherapy segment over the forecast period.

Biopsy Devices is Expected to Grow registering the Highest CAGR Over The Forecast Period

Skin biopsies are a critical diagnostic tool for identifying conditions such as rashes, infections, and skin cancer. Techniques like shave biopsy, punch biopsy, excisional and incisional biopsies, and lymph node biopsies are commonly used. In this procedure, dermatologists extract a small skin sample to diagnose diseases, including cancer, and analyze its histopathology. The increasing reliance on these procedures enhances the adoption of biopsy devices, thereby driving growth in this segment.

Efforts to raise melanoma awareness are expected to significantly impact the adoption of diagnostic devices, including biopsy tools, over the forecast period. For instance, in July 2024, Castle Biosciences, Inc. partnered with Teddi Mellencamp Arroyave, a wellness coach and stage II melanoma survivor, to launch a campaign focused on melanoma prevention, detection, and management. This initiative, which combines personal advocacy with public health goals, is likely to encourage the use of diagnostic tools such as biopsy devices, further supporting segment expansion.

Moreover, the introduction of innovative products is anticipated to contribute to market growth. For example, in June 2023, LabCorp introduced a liquid biopsy kit designed to detect various cancers, including melanoma. This advanced test analyzes cfDNA from blood samples to create a genomic profile of the tumor, identifying mutations in 33 genes linked to biomarkers for non-small cell lung cancer and melanoma. Such advancements in diagnostic technology are expected to increase the demand for biopsy devices, thereby boosting the segment's growth.

In conclusion, the combination of heightened awareness initiatives, technological advancements, and the launch of innovative products is driving the adoption of biopsy devices. These factors collectively position the biopsy devices segment for robust growth in the United States melanoma diagnostics and therapeutics market during the forecast period.

United States Melanoma Diagnostics And Therapeutics Industry Overview

The United States melanoma diagnostics and therapeutics market is semi-consoldated, with the presence of many key players. The market players are involved in market expansion, partnerships, new product development, and R&D to increase market penetration. Some of the market players are Abbott, Amgen, Inc., Bristol-Myers Squibb Company, Novartis AG, F. Hoffmann-La Roche Ltd, and others.

United States Melanoma Diagnostics And Therapeutics Market Leaders

United States Melanoma Diagnostics And Therapeutics Market News

• December 2024: Cosibelimab, a novel therapeutic targeting advanced cutaneous squamous cell carcinoma (CSCC), a type of skin cancer, has received approval from the United States Food and Drug Administration (FDA). This marks the first PD-L1 (Programmed Death-Ligand 1) inhibitor authorized for use in adults with CSCC that has metastasized or is unsuitable for surgical or radiation intervention.
• February 2024: Quest Diagnostics has introduced MelaNodal Predict, an advanced gene expression test aimed at supporting personalized treatment strategies for melanoma patients. As melanoma remains the most fatal form of skin cancer and one of the most frequently diagnosed cancers in the United States, this innovation addresses a critical need.